377 related articles for article (PubMed ID: 24878063)
1. Therapeutic drug monitoring in cancer--are we missing a trick?
Bardin C; Veal G; Paci A; Chatelut E; Astier A; Levêque D; Widmer N; Beijnen J
Eur J Cancer; 2014 Aug; 50(12):2005-9. PubMed ID: 24878063
[TBL] [Abstract][Full Text] [Related]
2. Review of therapeutic drug monitoring of anticancer drugs part two--targeted therapies.
Widmer N; Bardin C; Chatelut E; Paci A; Beijnen J; Levêque D; Veal G; Astier A
Eur J Cancer; 2014 Aug; 50(12):2020-36. PubMed ID: 24928190
[TBL] [Abstract][Full Text] [Related]
3. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological Profile and Pharmacogenomics of Anti-Cancer Drugs Used for Targeted Therapy.
Di Francia R; De Monaco A; Saggese M; Iaccarino G; Crisci S; Frigeri F; De Filippi R; Berretta M; Pinto A
Curr Cancer Drug Targets; 2018; 18(5):499-511. PubMed ID: 28183252
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic drug monitoring in cancer chemotherapy.
Bach DM; Straseski JA; Clarke W
Bioanalysis; 2010 May; 2(5):863-79. PubMed ID: 21083218
[TBL] [Abstract][Full Text] [Related]
6. Therapeutic Drug Monitoring of Targeted Therapy in Metastatic Renal Cell Carcinoma.
Liao D; Shangguan D; Yao D; Zhu Q; Cao L; Long M; Wu Y; Xiang D; Yang N
Protein Pept Lett; 2018; 25(6):528-533. PubMed ID: 29848258
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring of cancer chemotherapy.
Alnaim L
J Oncol Pharm Pract; 2007 Dec; 13(4):207-21. PubMed ID: 18045780
[TBL] [Abstract][Full Text] [Related]
8. Evidence for therapeutic drug monitoring of targeted anticancer therapies.
Gao B; Yeap S; Clements A; Balakrishnar B; Wong M; Gurney H
J Clin Oncol; 2012 Nov; 30(32):4017-25. PubMed ID: 22927532
[TBL] [Abstract][Full Text] [Related]
9. Target concentration intervention in oncology: where are we at?
Saleem M; Dimeski G; Kirkpatrick CM; Taylor PJ; Martin JH
Ther Drug Monit; 2012 Jun; 34(3):257-65. PubMed ID: 22585183
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic drug monitoring of targeted anticancer therapy.
Decosterd LA; Widmer N; Zaman K; Cardoso E; Buclin T; Csajka C
Biomark Med; 2015; 9(9):887-93. PubMed ID: 26333311
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic drug monitoring of oral targeted antineoplastic drugs.
Mueller-Schoell A; Groenland SL; Scherf-Clavel O; van Dyk M; Huisinga W; Michelet R; Jaehde U; Steeghs N; Huitema ADR; Kloft C
Eur J Clin Pharmacol; 2021 Apr; 77(4):441-464. PubMed ID: 33165648
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions with solid tumour-targeted therapies.
Thomas-Schoemann A; Blanchet B; Bardin C; Noé G; Boudou-Rouquette P; Vidal M; Goldwasser F
Crit Rev Oncol Hematol; 2014 Jan; 89(1):179-96. PubMed ID: 24041628
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic principles of immunosuppressive drugs.
Budde K; Glander P
Ann Transplant; 2008; 13(3):5-10. PubMed ID: 18806727
[TBL] [Abstract][Full Text] [Related]
14. The role of therapeutic drug monitoring in the management of patients with human immunodeficiency virus infection.
Pretorius E; Klinker H; Rosenkranz B
Ther Drug Monit; 2011 Jun; 33(3):265-74. PubMed ID: 21566505
[TBL] [Abstract][Full Text] [Related]
15. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011.
Hiemke C; Baumann P; Bergemann N; Conca A; Dietmaier O; Egberts K; Fric M; Gerlach M; Greiner C; Gründer G; Haen E; Havemann-Reinecke U; Jaquenoud Sirot E; Kirchherr H; Laux G; Lutz UC; Messer T; Müller MJ; Pfuhlmann B; Rambeck B; Riederer P; Schoppek B; Stingl J; Uhr M; Ulrich S; Waschgler R; Zernig G
Pharmacopsychiatry; 2011 Sep; 44(6):195-235. PubMed ID: 22053351
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics and therapeutic drug monitoring of anticancer agents].
Marquet P; Rousseau A
Bull Cancer; 2008 Oct; 95(10):903-9. PubMed ID: 19004719
[TBL] [Abstract][Full Text] [Related]
17. Imatinib, sunitinib and pazopanib: From flat-fixed dosing towards a pharmacokinetically guided personalized dose.
Westerdijk K; Desar IME; Steeghs N; van der Graaf WTA; van Erp NP;
Br J Clin Pharmacol; 2020 Feb; 86(2):258-273. PubMed ID: 31782166
[TBL] [Abstract][Full Text] [Related]
18. [Issues in therapeutic drug monitoring evaluation].
Paintaud G; Le Guellec C; Furet Y; Autret-Leca E
Therapie; 2001; 56(3):245-9. PubMed ID: 11475802
[TBL] [Abstract][Full Text] [Related]
19. Monte Carlo simulations of the clinical benefits from therapeutic drug monitoring of sunitinib in patients with gastrointestinal stromal tumours.
Goulooze SC; Galettis P; Boddy AV; Martin JH
Cancer Chemother Pharmacol; 2016 Jul; 78(1):209-16. PubMed ID: 27295055
[TBL] [Abstract][Full Text] [Related]
20. Erlotinib: another candidate for the therapeutic drug monitoring of targeted therapy of cancer? A pharmacokinetic and pharmacodynamic systematic review of literature.
Petit-Jean E; Buclin T; Guidi M; Quoix E; Gourieux B; Decosterd LA; Gairard-Dory AC; Ubeaud-Séquier G; Widmer N
Ther Drug Monit; 2015 Feb; 37(1):2-21. PubMed ID: 24831652
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
